Oralair®: Sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis

Expert Review of Clinical Immunology

Volumn 7, Issue 4, 2011, Pages 437-444

  Hong, Jison ^a   Bielory, Leonard ^b,c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b STARx Allergy and Asthma Center   (United States)

^c Center for Environmental Prediction   (United States)

Author keywords

allergen; allergic rhinoconjunctivitis dose response; grass pollen tablet; index of reactivity; subcutaneous immunotherapy; sublingual immunotherapy

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; EXCIPIENT; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGIC AGENT; MONOAMINE OXIDASE INHIBITOR; ORALAIR; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALLERGENICITY; ALLERGIC REACTION; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIBODY RESPONSE; ARTICLE; ASTHENIA; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BREAST FEEDING; BRONCHITIS; CLINICAL ASSESSMENT TOOL; CONJUNCTIVAL HYPEREMIA; COUGHING; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; DYSPHONIA; DYSPNEA; EAR DISEASE; EAR PRURITUS; ECZEMA; GASTROINTESTINAL PAIN; GLOSSITIS; GRASS POLLEN; GRASS POLLEN ALLERGIC RHINOCONJUNCTIVITIS; HUMAN; HYPERSENSITIVITY; HYPERTENSIVE CRISIS; HYPESTHESIA; HYPOTENSION; IMMUNE RESPONSE; INCIDENCE; LACTATION; LACTOSE INTOLERANCE; LARYNX DISORDER; LARYNX EDEMA; LIP DISEASE; MOUTH DISCOMFORT; MOUTH EDEMA; MOUTH INFLAMMATION; MOUTH PAIN; MUSCULOSKELETAL PAIN; NAUSEA; NEOPLASM; NOSE CONGESTION; OCULAR PRURITUS; ODYNOPHAGIA; ORAL BLISTER; ORAL PRURITUS; ORAL SURGERY; OTALGIA; PATIENT MONITORING; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RHINOCONJUNCTIVITIS; RHINOPHARYNGITIS; RHINORRHEA; SCORING SYSTEM; SIDE EFFECT; SKIN EDEMA; SKIN PRURITUS; SKIN TEST; SNEEZING; STOMATITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; THORAX PAIN; THROAT IRRITATION; THROAT TIGHTNESS; TONGUE SWELLING; TONSILLITIS; TREATMENT DURATION; VACCINATION; VOMITING;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; CONJUNCTIVITIS; DESENSITIZATION, IMMUNOLOGIC; EUROPE; POACEAE; POLLEN; RHINITIS; RHINITIS, ALLERGIC, SEASONAL; UNITED STATES;

EID: 79960909135     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.36     Document Type: Article

References (35)

1. Ciprandi G, Puccinelli P, Scurati S et al. Characteristics of rhinitis and asthma in patients referring to allergy specialist. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology. London, UK, 5-9 June 2010 (P1698)
2. Ciprandi G, Incorvaia C, Puccinelli P, Scurati S, Masieri S, Frati F. The POLISMAIL lesson: sublingual immunotherapy may be prescribed also in polysensitized patients. Int. J Immunopathol. Pharmacol. 23(2), 637-640 (2010)
3. Noon L, Cantab BC. Prophylactic inoculation against hay fever. Lancet 177(4580), 1572-1573 (1911)
4. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin. Immunol. 93(3), 556-566 (1994) (Pubitemid 24105060)
5. Lofkvist T, Agrell B, Dreborg S, Svensson G. Effects of immunotherapy with a purified standardized allergen preparation of Dermatophagoides farina in adults with perennial allergic rhinoconjunctivitis. Allergy 49(2), 100-107 (1994)
6. Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol. 77(1), 74-80 (1996) (Pubitemid 26324156)
7. Lowell FC, Frankline W. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J. Med 273(13), 675-679 (1965)
8. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. J Allergy Clin. Immunol. 85(3), 606-611 (1990) (Pubitemid 20099004)
9. Del Prete A, Loffredo C, Carderopoli A, Caparello O, Verde R, Sebastian A. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthal. (Copenh.) 72(5), 631-634 (1994) (Pubitemid 24370776)
10. Gaglani B, Borish L, Bartelson BL, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced allergic rhinitis. Ann Allergy Asthma Immunol. 79(3), 259-265 (1997) (Pubitemid 27499982)
11. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 41(2), 131-140 (1986) (Pubitemid 16044354)
12. Balda BR, Wolf H, Baumgarten C et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 53(8), 740-748 (1998) (Pubitemid 28374754)
13. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin. Immunol. 120(6), 1338-1345 (2007) (Pubitemid 350225683)
14. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin. Immunol. 111(3), 437-448; quiz 449 (2003) (Pubitemid 36337857)
15. Morris DL. Treatment of respiratory disease with ultra-small doses of antigens. Ann Allergy 28(10), 494-500 (1970)
16. Horak F, Stubner P, Berger UE, Marks B, Toth J, Jager S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig. Allergol. Clin Immunol. 8(3), 165-171 (1998) (Pubitemid 28342473)
17. Mascarell L, Saint-Lu N, Moussu H et al. Macrophage-like cells play a crucial role in tolerance induction via the sublingual route. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology. London, UK, 5-9 June 2010
18. Canonica GW, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(Suppl. 91), 1-59 (2009)
19. Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin. Immunol. 113(6), 1129-1136 (2004) (Pubitemid 38857996)
20. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin. Immunol. 79(4), 660-677 (1987) (Pubitemid 17056923)
21. Calderon M, Mosges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 65(4), 420-434 (2010)
22. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin. Immunol. 121(2), 512-518 e2 (2008)
23. Pradalier A, Basset D, Claudel A et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54(8), 819-828 (1999) (Pubitemid 29402164)
24. Didier A. Future developments in sublingual immunotherapy. Allergy 61(Suppl. 81), 29-31 (2006)
25. Moingeon P, Hrabina M, Bergmann KC et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int. Arch Allergy Immunol. 146(4), 338-342 (2008) (Pubitemid 351957409)
26. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp. Allergy 40(4), 598-606 (2010)
27. Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin. Immunol. 124(3), 471-477, 477 e1 (2009)
28. Stelmach I, Kaczmarek-Wozniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen. Clin Exp. Allergy 39(3), 401-408 (2009)
29. Machida H, Nakagami T, Watanabe I. Local ocular immunotherapy for experimental allergic conjunctivitis. Jpn J. Ophthalmol. 44(6), 634-638, (2000)
30. Magone MT, Chan CC, Beck L, Whitcup SM, Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J Immunol. 30(7), 1841-1850 (2000) (Pubitemid 30456180)
31. Miyazaki D, Liu G, Clark L, Ono SJ. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences. Invest. Ophthalmol. Vis. Sci. 41(12), 3850-3855 (2000)
32. Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease. Immunol. Rev. 179, 102-118 (2001) (Pubitemid 32171278)
33. Moingeon P. Recombinant allergens for sublingual immunotherapy. Presented at: 29th Congress of the European Academy of Allergy and Clinical Immunology. London, UK, 5-9 June 2010
34. Stallergenes: Positive Results for Oralair(R) Phase III Trial in the USA www.prnewswire.com/news-releases/ stallergenes-positive-results-for-oralairr- phase-iii-trial-in-the-usa-91447739.html
35. ORALAIR 100 IR & 300 IR sublingual tablets: summary of product characteristics www.stallergenes.com/fileadmin/images/ corporate/gallery/ Documents-pdf/2010-10-Oralair-fin-MRP-RCP.pdf